Search Term:

bioreactors


March 19, 2019: New lab will serve as a dedicated platform where the industry can access shared resources including equipment, expertise and project work to find innovative solutions to manufacturing needs for biologic medicines, such as cell-based immunotherapies

March 11, 2019: Pall Biotech to integrate and distribute Broadley-James’ advanced single-use probe and flow cell pH sensors; sensor will be integrated into Pall Biotech’s single-use technologies

September 11, 2018: Pall and Aetos partner to combine bioreactors, mixing and storage, and downstream technologies with cell lines and manufacturing processes for expedited biosimilars development

September 3, 2018: Celltheon and Pall to provide an integrated, cost-effective, time efficient end-to-end solution for research and bioproduction to expedite drug development and provide solutions for unmet needs in bioprocessing

July 23, 2018: New partnership to integrate novel biologics and biosimilars process know-how and regulatory experience from molecule selection to full commercialization, with efficient upstream and downstream process equipment and facility design solutions for manufacturers

April 15, 2018: Patrnership to bring together Artesyn Biosolutions' valves and fluid handling technologies with Pall's Allegro solutions including bioreactors, range of downstream automated equipment and mixers to enable customers to implement efficient single-use manufacturing lines

September 25, 2017: Brammer Bio utilizes Pall's critical process solutions and process support, to help focus on building on more than 100 executed projects and 150 clinical cell and gene therapy lots in Florida, including many first-in-human trials

July 26, 2017: Announcing a new bioreactor control system - the first in Pall's next generation of unifying technologies for a seamless, fully controlled, and value-based user experience

October 5, 2016: New collaboration to deliver complete solutions for industrial-scale bioreactor expansion of human Mesenchymal Stem/Stromal Cells (hMSCs), to accelerate product development, reduce clinical translation timelines and streamline the commercialization pathway for stem cell-based therapies

October 4, 2016: Multiple breakthrough technologies announced to enable integrated, process-scale continuous production of biotherapies in single-use format